6% Stake of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Owned by PAULSON & COMPANY . INC.

PAULSON & COMPANY . INC.

stated that they own 6% of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a Form 13D disclosure that was filed with the Securities and Exchange Commission on Wednesday, August 9th. The investor owns 20,839,038 shares of the stock worth $299,873,757. The filing is available through EDGAR at this hyperlink.

PAULSON & COMPANY . INC.

provided the following explanation of their ownership:

Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Warning: file_get_contents(https://whalewisdom.com
20,839,038
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in shares of Valeant Pharmaceuticals International by 86.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 576,634 shares of the specialty pharmaceutical company’s stock worth $8,372,000 after buying an additional 268,116 shares during the period. Guggenheim Capital LLC increased its stake in shares of Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 2,752 shares during the period. Gulf International Bank UK Ltd increased its stake in shares of Valeant Pharmaceuticals International by 1.1% in the first quarter. Gulf International Bank UK Ltd now owns 98,323 shares of the specialty pharmaceutical company’s stock worth $1,084,000 after buying an additional 1,100 shares during the period. Capstone Asset Management Co. increased its stake in shares of Valeant Pharmaceuticals International by 13.6% in the first quarter. Capstone Asset Management Co. now owns 32,988 shares of the specialty pharmaceutical company’s stock worth $364,000 after buying an additional 3,940 shares during the period. Finally, Verde Servicos Internacionais S.A. acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $271,000. 50.96% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded up 0.35% during midday trading on Friday, hitting $14.39. The company had a trading volume of 10,472,002 shares. Valeant Pharmaceuticals International, Inc. has a 12-month low of $8.31 and a 12-month high of $32.74. The company’s 50 day moving average is $16.18 and its 200 day moving average is $13.40. The stock’s market cap is $5.02 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. During the same period in the previous year, the company posted ($0.88) EPS. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. On average, equities analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “6% Stake of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Owned by PAULSON & COMPANY . INC.” was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.com-unik.info/2017/08/19/paulson-company-inc-declares-ownership-of-6-stake-in-valeant-pharmaceuticals-international-inc-nysevrx-updated.html.

A number of analysts have issued reports on VRX shares. Wells Fargo & Company reaffirmed an “underperform” rating on shares of Valeant Pharmaceuticals International in a report on Monday, June 12th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Valeant Pharmaceuticals International in a report on Tuesday, May 9th. Zacks Investment Research downgraded Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Thursday, July 13th. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Finally, BidaskClub raised Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Valeant Pharmaceuticals International has an average rating of “Hold” and an average target price of $17.31.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

What are top analysts saying about Valeant Pharmaceuticals International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit